Acesso livre
Acesso livre

Arquivos do dia: Novembro 16, 2021

Documento de consenso IDSA/ASM | Aplicações clínicas e de prevenção de infecção da genotipagem do SARS-CoV-2.

16 Nov, 2021 | 12:48h

Clinical and Infection Prevention Applications of SARS-CoV-2 Genotyping: An IDSA/ASM Consensus Review Document – Clinical Infectious Diseases

Comunicado de imprensa: New review article outlines potential of SARS-CoV-2 genetic sequencing in patient care – American Society for Microbiology

Estudo randomizado | Imunoglobulinas intravenosas não melhoram os desfechos em pacientes com síndrome da angústia respiratória aguda moderada a grave associada a COVID-19.

16 Nov, 2021 | 12:47h

Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial – The Lancet Respiratory Medicine

 

Comentário no Twitter

 

Revisão | Trombocitopenia trombótica imune induzida por vacina.

16 Nov, 2021 | 12:46h

Vaccine-induced immune thrombotic thrombocytopenia – The Lancet Haematology

Conteúdos relacionados:

Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance.

Clinical features of vaccine-induced immune thrombocytopenia and thrombosis.

Review: Clinical characteristics and pharmacological management of COVID-19 vaccine–induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis.

Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.

Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (vários artigos e fontes sobre o tema)

 

Comentário no Twitter

 

Covid: Áustria impõe lockdown a não vacinados.

16 Nov, 2021 | 12:44h

Covid: Austria introduces lockdown for unvaccinated – BBC

Ver também: Austria orders nationwide lockdown for the unvaccinated – Associated Press

Covid-19: produção global de vacinas é desordenada e a escassez é decorrente de outros fatores além da acumulação por alguns países.

16 Nov, 2021 | 12:43h

Covid-19: global vaccine production is a mess and shortages are down to more than just hoarding – The BMJ

 

Comentário no Twitter

 

Pílula da Pfizer é o mais recente tratamento contra COVID a se mostrar promissor.

16 Nov, 2021 | 12:41h

Pfizer’s pill is the latest COVID treatment to show promise. Here are some more – The Conversation

Conteúdos relacionados:

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

Merck v Pfizer: como os dois antivirais contra COVID funcionam e serão utilizados.

16 Nov, 2021 | 12:38h

Merck v Pfizer: here’s how the two new COVID antiviral drugs work and will be used – The Conversation

Conteúdos relacionados:

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

Consenso internacional 2021 sobre ressuscitação cardiopulmonar e cuidado cardiovascular de emergência com recomendações de tratamento.

16 Nov, 2021 | 12:36h

2021 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations: Summary From the Basic Life Support; Advanced Life Support; Neonatal Life Support; Education, Implementation, and Teams; First Aid Task Forces; and the COVID-19 Working Group – Circulation (para versão HTML, clique aqui)

Principais tópicos a saber: International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations (CoSTR) – American Heart Association

Novo relatório da OMS mapeia as barreiras à disponibilidade de insulina e sugere ações que promovam o acesso universal – “100 anos depois de sua descoberta, a insulina ainda está fora do alcance de muitos que vivem com diabetes.”

16 Nov, 2021 | 12:34h

Comunicado de imprensa: New WHO report maps barriers to insulin availability and suggests actions to promote universal access – World Health Organization

Relatório: Keeping the 100-year-old promise: making insulin access universal – World Health Organization

Comentário: Half the People Living with Diabetes Can’t Afford Insulin, WHO Report Shows – Health Policy Watch

Conteúdos relacionados:

Editorial | Insulin for all: a hope yet to be realized.

One hundred years of insulin therapy.

The state of diabetes treatment coverage in 55 low-income and middle-income countries – fewer than one in ten people with diabetes in LMICs receive comprehensive care such as low-cost medicines to reduce blood sugar, blood pressure and cholesterol levels, in addition to counseling on diet, exercise and weight.

 

Comentário no Twitter (fio – clique para saber mais)

 

#AHA21 – M-A | Entre pacientes com obstrução em coronária esquerda, não houve diferença estatisticamente significativa na mortalidade em 5 anos por todas as causas entre intervenção coronariana percutânea com stents farmacológicos vs. cirurgia de revascularização miocárdica.

16 Nov, 2021 | 12:33h

Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis – The Lancet (necessário cadastro gratuito)

Comentário: No Mortality Difference Between PCI and CABG for Left Main PCI: Meta-analysis – TCTMD

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.